Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Vincerx Pharma, Inc. (NASDAQ: VINC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024